Atossa Therapeutics, Inc.
ATOS · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Market Cap | – | $107,211 | $86,918 | $119,543 |
| - Cash | $51,845 | $57,857 | $65,116 | $71,084 |
| + Debt | $0 | $0 | $0 | $0 |
| Enterprise Value | – | $49,354 | $21,802 | $48,459 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Gross Profit | -$4 | $0 | $0 | -$4 |
| % Margin | – | – | – | – |
| EBITDA | -$8,688 | -$9,036 | -$7,410 | -$7,147 |
| % Margin | – | – | – | – |
| Net Income | -$8,692 | -$8,423 | -$6,718 | -$6,347 |
| % Margin | – | – | – | – |
| EPS Diluted | -0.07 | -0.065 | -0.052 | -0.05 |
| % Growth | -7.4% | -25.4% | -3.8% | – |
| Operating Cash Flow | -$6,005 | -$7,259 | -$5,959 | -$7,051 |
| Capital Expenditures | -$7 | $0 | -$9 | $0 |
| Free Cash Flow | -$6,012 | -$7,259 | -$5,968 | -$7,051 |